No Data
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
WHO Extends Mpox Emergency; Canada Reports First Clade I Case
Trump Nominates Marty Makary For FDA Commissioner
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
First Mpox Case Linked to African Outbreak Reported in U.S.
Sell-off of US vaccine stocks intensifies! Analyst: Little Kennedy brings uncertainty to the entire industry.
1. On Friday Eastern Time, vaccine manufacturers' stocks plummeted as Donald Trump selected vaccine skeptic Kennedy as Health Secretary, causing industry uncertainty. Moderna, Novavax, Pfizer, and other stock prices were all affected. 2. Analysts pointed out that Kennedy's anti-vaccine stance may weaken public trust in vaccines, leading to a decrease in the vaccination rate in the USA, increasing the risk of outbreaks of diseases such as measles and whooping cough.
No Data
